Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent cliff
Pharma
Novartis stares down $16.7B post-2030 patent cliff
Three of Novartis’ largest current growth pillars are projected to plunge from $23.9 billion in sales in 2030 to just $7.2 billion in 2035.
Angus Liu
Nov 19, 2026 11:45am
AZ emerges victorious in lawsuit over Soliris antitrust claims
Nov 17, 2026 11:25am
Sandoz sets ambitious goal to grow biosimilar bona fides by 2040
Sep 8, 2026 2:45pm
J&J's immunology portfolio compensates for Stelara's LOE
Jul 15, 2026 11:30am
Novartis dismisses 322 more staffers based out of US headquarters
Jul 7, 2026 11:41am
How biosimilar developers are embracing next phase of US market
Jul 6, 2026 10:03am